Cargando…

Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems

Despite decades of research and billions in global investment, there remains no preventative or curative treatment for any neurodegenerative condition, including Parkinson’s disease (PD). Arguably, the most promising approach for neuroprotection and neurorestoration in PD is using growth factors whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jarrin, Sarah, Hakami, Abrar, Newland, Ben, Dowd, Eilís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543245/
https://www.ncbi.nlm.nih.gov/pubmed/33896851
http://dx.doi.org/10.3233/JPD-212662
_version_ 1784589601815396352
author Jarrin, Sarah
Hakami, Abrar
Newland, Ben
Dowd, Eilís
author_facet Jarrin, Sarah
Hakami, Abrar
Newland, Ben
Dowd, Eilís
author_sort Jarrin, Sarah
collection PubMed
description Despite decades of research and billions in global investment, there remains no preventative or curative treatment for any neurodegenerative condition, including Parkinson’s disease (PD). Arguably, the most promising approach for neuroprotection and neurorestoration in PD is using growth factors which can promote the growth and survival of degenerating neurons. However, although neurotrophin therapy may seem like the ideal approach for neurodegenerative disease, the use of growth factors as drugs presents major challenges because of their protein structure which creates serious hurdles related to accessing the brain and specific targeting of affected brain regions. To address these challenges, several different delivery systems have been developed, and two major approaches—direct infusion of the growth factor protein into the target brain region and in vivo gene therapy—have progressed to clinical trials in patients with PD. In addition to these clinically evaluated approaches, a range of other delivery methods are in various degrees of development, each with their own unique potential. This review will give a short overview of some of these alternative delivery systems, with a focus on ex vivo gene therapy and biomaterial-aided protein and gene delivery, and will provide some perspectives on their potential for clinical development and translation.
format Online
Article
Text
id pubmed-8543245
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-85432452021-11-10 Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems Jarrin, Sarah Hakami, Abrar Newland, Ben Dowd, Eilís J Parkinsons Dis Review Despite decades of research and billions in global investment, there remains no preventative or curative treatment for any neurodegenerative condition, including Parkinson’s disease (PD). Arguably, the most promising approach for neuroprotection and neurorestoration in PD is using growth factors which can promote the growth and survival of degenerating neurons. However, although neurotrophin therapy may seem like the ideal approach for neurodegenerative disease, the use of growth factors as drugs presents major challenges because of their protein structure which creates serious hurdles related to accessing the brain and specific targeting of affected brain regions. To address these challenges, several different delivery systems have been developed, and two major approaches—direct infusion of the growth factor protein into the target brain region and in vivo gene therapy—have progressed to clinical trials in patients with PD. In addition to these clinically evaluated approaches, a range of other delivery methods are in various degrees of development, each with their own unique potential. This review will give a short overview of some of these alternative delivery systems, with a focus on ex vivo gene therapy and biomaterial-aided protein and gene delivery, and will provide some perspectives on their potential for clinical development and translation. IOS Press 2021-09-22 /pmc/articles/PMC8543245/ /pubmed/33896851 http://dx.doi.org/10.3233/JPD-212662 Text en © 2021 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Jarrin, Sarah
Hakami, Abrar
Newland, Ben
Dowd, Eilís
Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems
title Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems
title_full Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems
title_fullStr Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems
title_full_unstemmed Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems
title_short Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems
title_sort growth factor therapy for parkinson’s disease: alternative delivery systems
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543245/
https://www.ncbi.nlm.nih.gov/pubmed/33896851
http://dx.doi.org/10.3233/JPD-212662
work_keys_str_mv AT jarrinsarah growthfactortherapyforparkinsonsdiseasealternativedeliverysystems
AT hakamiabrar growthfactortherapyforparkinsonsdiseasealternativedeliverysystems
AT newlandben growthfactortherapyforparkinsonsdiseasealternativedeliverysystems
AT dowdeilis growthfactortherapyforparkinsonsdiseasealternativedeliverysystems